Wikipedia -WSS

Wikipedia

author：explore 2025-09-27 11:58:14 - browse：37415

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Robert F. Kennedy is pitching centrism on health, even on abortion

knowledge

WSS

To avoid data mishandling cases, universities eye AI and other tools

Robert F. Kennedy is pitching centrism on health, even on abortion

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Vaccine advisory panel ACIP left half staffed by HHS

leisure time

Wikipedia

explore

Medicare proposal to cover medical devices draws a mixed reaction

Boston's new lab space is opening empty

The cancer drug shortage isn’t new — and neither are the solutions

Vaccine advisory panel ACIP left half staffed by HHS

Supreme Court strikes down use of affirmative action

Medical mystery: When a cough is not just a cough

As demand for Covid shots wanes, Moderna seeks its next success

Industry veterans launch new biotech VC with $310M

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Private equity deals in Medicare Advantage declines

entertainment

Medical mystery: When a cough is not just a cough

UCLA team creates talking throat patch for voice disorders

Industry veterans launch new biotech VC with $310M

Male and female sex labels in research insufficient, scientists say

Ebola: Gilead Sciences antiviral shows promise as new treatment

Senators start work on Medicare physician payment reform

entertainment

knowledge

leisure time

Wikipedia